A portosystemic shunt is an abnormal blood vessel that allows blood from the gut to flow directly into the general circulation, bypassing the liver entirely. Normally, blood from the intestines travels through the portal vein to the liver, where toxins like ammonia are filtered out before the blood reaches the rest of the body. When a shunt is present, those toxins skip the liver’s filtration system and circulate freely, eventually reaching the brain and other organs. This is the core problem: the liver can’t do its job if blood never passes through it.
How a Portosystemic Shunt Works
The portal vein is a major blood vessel that collects nutrient-rich (but toxin-laden) blood from the stomach, intestines, and spleen and delivers it to the liver. The liver processes this blood, breaking down harmful substances like ammonia, a natural byproduct of protein digestion. In a portosystemic shunt, an abnormal vessel creates a shortcut, routing some or all of that blood away from the liver and into veins that carry it straight to the heart.
The shunting vessel can drain into several different veins, including the large vein running through the abdomen (the inferior vena cava), a hepatic vein, or other systemic veins. The amount of blood that bypasses the liver varies. In some cases, nearly all portal blood is diverted. In others, only a portion takes the shortcut while the rest follows the normal route through the liver.
Congenital vs. Acquired Shunts
Portosystemic shunts fall into two broad categories based on their origin. Congenital shunts are present from birth and result from abnormal development of blood vessels during fetal growth. One common form, called a patent ductus venosus, occurs when a vessel that normally exists in the fetus (the ductus venosus, which allows oxygen-rich blood from the umbilical cord to bypass the fetal liver) fails to close after birth. Other congenital shunts arise from abnormal connections between the developing venous systems that persist instead of disappearing as they should.
Acquired shunts develop later in life as a consequence of existing liver disease, most commonly cirrhosis. When the liver becomes scarred and stiff, blood pressure in the portal vein rises, a condition called portal hypertension. The body responds by opening up alternative pathways for blood to flow, essentially creating new shunts to relieve the pressure. These acquired shunts tend to involve multiple small vessels rather than a single large one.
Types Based on Location
Congenital shunts are further classified by where the abnormal vessel sits relative to the liver. Extrahepatic shunts run outside the liver, connecting the portal system to a systemic vein before the blood ever enters the liver. They come in two forms: Type 1, where all portal blood is completely diverted into the systemic circulation with no portal branches inside the liver at all, and Type 2, where the internal portal system is intact but some blood is siphoned off through a side connection.
Intrahepatic shunts occur inside the liver itself, creating abnormal connections between portal vein branches and the hepatic veins or the inferior vena cava. These range from a single large vessel to multiple small communications scattered across both lobes of the liver. Of all published congenital cases in one review, extrahepatic shunts were somewhat more common, with 185 extrahepatic cases compared to 131 intrahepatic ones.
Symptoms of a Portosystemic Shunt
The most significant consequence of a portosystemic shunt is hepatic encephalopathy, a condition where toxins that the liver would normally remove build up in the bloodstream and affect the brain. Ammonia is the primary culprit. When blood carrying high levels of ammonia reaches the brain, it causes a range of neurological symptoms: confusion, disorientation, personality changes, erratic behavior, poor coordination, and in severe cases, profound drowsiness or loss of consciousness.
Symptoms can be subtle at first, especially in congenital cases where they may appear early in life. Gastrointestinal signs like poor appetite, vomiting, and stunted growth are common in young animals with congenital shunts. In people with acquired shunts from liver disease, encephalopathy often worsens after eating protein-heavy meals (since protein digestion produces more ammonia) or during infections, dehydration, or constipation. The severity can fluctuate, with episodes of confusion alternating with relatively clear periods.
How Portosystemic Shunts Are Diagnosed
Blood tests are typically the first step. Two key markers point toward a shunt: blood ammonia levels and bile acid concentrations. Bile acids are particularly useful because the liver normally recycles them from the blood after meals. When blood bypasses the liver, bile acids accumulate in the bloodstream at abnormally high levels. In dogs, bile acid testing has a sensitivity of 93% for detecting shunts, while ammonia testing catches about 85-91% of cases depending on the cutoff values used.
Imaging confirms the diagnosis and maps the anatomy of the shunt. Ultrasound is often the initial imaging choice because it’s widely available and non-invasive, but it misses a significant number of shunts, detecting only about 68% in one comparative study. CT angiography is far more reliable, with a 96% detection rate and much better accuracy in pinpointing exactly where the shunt originates and where it drains. CT was 5.5 times more likely to correctly identify or rule out a shunt compared to ultrasound.
Medical Management
Medical treatment focuses on reducing the toxins that the liver is failing to filter. Diet is a cornerstone: lower-protein diets with highly digestible protein sources leave less undigested protein in the gut for bacteria to convert into ammonia. This alone can meaningfully reduce symptoms.
Lactulose, a synthetic sugar that isn’t absorbed by the body, works through several mechanisms in the colon. It lowers the pH, which converts ammonia into a form (ammonium) that the gut lining can’t absorb, effectively trapping it in the intestines for excretion. It also speeds up transit through the gut, giving bacteria less time to produce ammonia. Antibiotics like metronidazole target the ammonia-producing bacteria directly, reducing the amount of ammonia generated in the first place. These treatments are often used together, especially to stabilize symptoms before surgery or in cases where surgery isn’t an option.
Surgical Treatment
For congenital shunts, surgery aims to close the abnormal vessel and redirect blood flow back through the liver. The traditional approach is direct ligation, where a surgeon ties off the shunting vessel. A newer technique uses an ameroid constrictor, a ring-shaped device placed around the shunt vessel that slowly swells over weeks, gradually narrowing and closing the vessel. In a comparison of the two techniques, the ameroid constrictor cut surgery time roughly in half and produced fewer complications during and after the procedure, while achieving comparable long-term results.
Gradual closure matters because the liver and portal system need time to adapt. If a shunt that has been carrying most of the portal blood is closed suddenly, the portal vein pressure can spike dangerously. Gradual methods like the ameroid constrictor allow the liver’s blood vessels to slowly expand and accommodate increasing blood flow.
TIPS: A Shunt Created on Purpose
Confusingly, doctors sometimes create a portosystemic shunt deliberately. A transjugular intrahepatic portosystemic shunt (TIPS) is a procedure where an interventional radiologist places a stent inside the liver to connect the portal vein to a hepatic vein. This is done to relieve dangerous portal hypertension in patients with severe liver disease, particularly those experiencing life-threatening bleeding from swollen veins (varices) or fluid buildup in the abdomen (ascites).
TIPS procedures have a technical success rate of about 98%, and clinical success rates of 85% for controlling bleeding and 95% for resolving fluid buildup. The tradeoff is that by diverting portal blood past the liver, TIPS can trigger hepatic encephalopathy in 5 to 35% of patients. Severe, disabling encephalopathy occurs in 1 to 3% of cases, sometimes requiring the shunt to be narrowed or closed. Median survival after TIPS is roughly 43 months, though this largely reflects the severity of the underlying liver disease rather than the shunt itself. Shunt dysfunction requiring additional procedures occurs in about 36% of patients over time, though assisted patency rates remain high at 87% after six years.
Long-Term Outlook
Prognosis depends heavily on the type of shunt and the underlying cause. Congenital shunts in otherwise healthy individuals (or animals) often have good outcomes after surgical correction, particularly when the liver has the capacity to grow and take on its normal filtering role once blood flow is restored. The liver is remarkably adaptable, and many patients see significant improvement in neurological symptoms, growth, and overall health after successful closure.
Acquired shunts tied to advanced liver disease carry a more guarded prognosis because the underlying liver damage remains. In these cases, medical management and procedures like TIPS can control symptoms and prevent life-threatening complications, but the long-term outcome is closely tied to the progression of the liver disease itself. The 30-day mortality rate after TIPS placement is about 8%, with survival rates declining over subsequent years as liver disease advances.